Federal Trade Commission Suffers Another Setback in Its Campaign to End Pharmaceutical Reverse-Settlement Agreements

William Michael, Aidan Synnott, Jun 27, 2012

For over a decade, the Federal Trade Commission has sought, with little success, to end “reverse settlement” payments among manufacturers of branded and generic pharmaceuticals. On April 25, 2012, the Eleventh Circuit Court of Appeals dealt another blow to the FTC’s campaign against reverse settlements.

In Federal Trade Commission v. Watson Pharmaceuticals, the Court affirmed the dismissal of a complaint alleging that a reverse settl